Binge Eating, Depression and Anxiety Outcomes After Sleeve Gastrectomy Versus Gastric Bypass: A Cohort Study
Binge Eating, Depression and Anxiety Outcomes Following Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y or One-Anastomosis Gastric Bypass: A Prospective Cohort Study
The goal of this clinical trial is to learn if the type of weight-loss surgery (sleeve gastrectomy or gastric bypass) affects binge eating, depression, and anxiety in adults with severe obesity. The main questions it aims to answer are:
Does sleeve gastrectomy lead to different changes in binge eating compared with gastric bypass?
Does the type of surgery lead to different changes in depression and anxiety symptoms?
Researchers will compare people who have sleeve gastrectomy with those who have gastric bypass to see if there are differences in binge eating, depression, and anxiety levels up to 12 months after surgery.
Participants will:
Complete questionnaires about eating habits, mood, anxiety, general health, and body image before surgery.
Undergo either a sleeve gastrectomy or a gastric bypass operation (both are standard care).
Follow a standard post-surgery diet plan.
Attend follow-up visits at 1 week, 2 weeks, 1 month, and then monthly for 12 months, where they will complete the same questionnaires again.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This prospective cohort study compares two standard-of-care bariatric surgical procedures - laparoscopic sleeve gastrectomy (SG) and laparoscopic gastric bypass (Roux-en-Y or one-anastomosis) - with respect to postoperative changes in binge eating, depression, and anxiety. A total of 100 morbidly obese patients (50 per arm) aged 18-60 years with a body mass index ≥35 kg/m² (or ≥30 kg/m² with at least one obesity-related comorbidity) will be recruited from the General Surgery department at Kasr Alainy Teaching Hospital, Cairo University.
The choice of procedure is determined by a preoperative multidisciplinary evaluation considering baseline BMI, presence of gastroesophageal reflux disease, type 2 diabetes mellitus, and patient preference after detailed counseling. All operations are performed under general anesthesia; SG uses a 36-Fr bougie.
Validated Arabic versions of the following instruments are administered at baseline and at each postoperative visit (1 week, 2 weeks, 1 month, and monthly thereafter for 12 months):
Binge Eating Scale (BES) - primary outcome for binge eating
Beck Depression Inventory-II (BDI-II) - primary outcome for depression
Beck Anxiety Inventory (BAI) - primary outcome for anxiety
General Health Questionnaire-28 (GHQ-28)
Body Shape Questionnaire-14 (BSQ-14)
Eating Attitude Test-26 (EAT-26)
Secondary outcomes include changes in GHQ-28, BSQ-14, EAT-26 scores, and weight loss (absolute weight and BMI). Data will be analyzed using SPSS version 27, with appropriate parametric and non-parametric tests for between- and within-group comparisons. The significance level is set at p ≤ 0.05. The study is powered (80%, alpha 5%) to detect a difference in binge eating prevalence between SG (18.4%) and gastric bypass (1.3%) at one year, requiring 92 evaluable patients; 100 will be enrolled to accommodate potential loss to follow-up.
The study has been approved by the Cairo University Faculty of Medicine Research Ethics Committee (REC approval number N-64-2026, dated 7 March 2026). All participants provide written informed consent.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ahmed Eid Aziz, Lecturer
- Número de teléfono: +201127060844
- Correo electrónico: Ahmed-eid@kasralainy.edu.eg
Ubicaciones de estudio
-
-
Al-Manial Cairo
-
Cairo, Al-Manial Cairo, Egipto, 11956
- Reclutamiento
- Faculty of Medicine Cairo University
-
Contacto:
- Ahmed
-
Contacto:
- Ahmed Maher Abd Elmonim, Assistant professor
- Número de teléfono: +201031036313
- Correo electrónico: Ahmed.maher@kasralainy.edu.eg
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age between 18 and 60 years
- Body Mass Index (BMI) ≥ 35 kg/m² without comorbidities, OR BMI ≥ 30 kg/m² with at least one obesity-related medical comorbidity (e.g., type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia)
- Patient is generally fit for laparoscopic surgery and general anesthesia as determined by preoperative evaluation
- Patient agrees to comply with postoperative lifestyle changes (dietary modifications and follow-up schedule)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Age < 18 years or > 60 years
- Inability or unwillingness to adhere to postoperative lifestyle changes
- Contraindication to surgery: American Society of Anesthesiologists (ASA) class IV or higher
- History of receiving radiotherapy or chemotherapy for cancer treatment
- Active substance use disorder or uncontrolled severe psychiatric illness that would impair ability to comply with study procedures (e.g., active psychosis, severe suicidal ideation)
- Pregnant or breastfeeding women (pregnancy test performed preoperatively per institutional protocol)
- Previous bariatric surgery (revisional surgery excluded)
- Untreated thyroid disorder (e.g., hypothyroidism or hyperthyroidism)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Laparoscopic Sleeve Gastrectomy (SG)
Participants undergo laparoscopic sleeve gastrectomy using a 36-French bougie.
Standard perioperative and postoperative care according to bariatric surgery protocol.
Follow-up at 1 week, 2 weeks, 1 month, then monthly for 12 months.
Outcome assessments include Binge Eating Scale (BES), Beck Depression Inventory-II (BDI-II), Beck Anxiety Inventory (BAI), GHQ-28, BSQ-14, and EAT-26.
|
Laparoscopic sleeve gastrectomy performed using a 36-French bougie.
The greater curvature of the stomach is resected, creating a tubular gastric sleeve.
Standard perioperative care including antibiotic prophylaxis and DVT prophylaxis.
Postoperative liquid diet for 15 days, then soft diet for one month, followed by gradual introduction of regular diet avoiding fatty and high-sugar foods.
|
|
Comparador activo: Gastric Bypass (One Anastomosis or Roux-en-Y)
Participants undergo gastric bypass (either one anastomosis gastric bypass - OAGB, or Roux-en-Y gastric bypass - RYGB) based on preoperative multidisciplinary evaluation.
Standard perioperative and postoperative care.
Same follow-up schedule and outcome assessments as the SG arm.
|
Gastric bypass surgery performed either as Roux-en-Y gastric bypass (RYGB) or one anastomosis gastric bypass (OAGB) based on preoperative multidisciplinary evaluation.
Includes creation of a small gastric pouch and an anastomosis to the small bowel.
Standard perioperative and postoperative care same as sleeve gastrectomy.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Composite Mental Health Score (Simple Sum)
Periodo de tiempo: Baseline, 6 months, 12 months
|
Simple sum of raw scores from three scales: Binge Eating Scale (BES, 0-46) + Beck Depression Inventory-II (BDI-II, 0-63) + Beck Anxiety Inventory (BAI, 0-63).
Minimum total = 0 (best mental health).
Maximum total = 172 (worst mental health).
Higher score = worse mental health.
Primary endpoint is change from baseline to 12 months (lower score = improvement).
|
Baseline, 6 months, 12 months
|
|
Binge Eating Scale (BES) Score Change
Periodo de tiempo: Baseline, 6 months, 12 months
|
16-item self-report questionnaire.
Each item scored 0-3.
Total raw score range: minimum 0, maximum 46.
Higher score = more severe binge eating.
Clinical interpretation: 0-17 = no significant binge eating; 18-26 = moderate binge eating; 27-46 = severe binge eating.
|
Baseline, 6 months, 12 months
|
|
Beck Depression Inventory-II (BDI-II) Score Change
Periodo de tiempo: Baseline, 6 months, 12 months
|
21-item self-report inventory.
Each item scored 0-3.
Total raw score range: minimum 0, maximum 63.
Higher score = more severe depression.
Clinical interpretation: 0-13 = minimal depression; 14-19 = mild depression; 20-28 = moderate depression; 29-63 = severe depression.
|
Baseline, 6 months, 12 months
|
|
Beck Anxiety Inventory (BAI) Score Change
Periodo de tiempo: Baseline, 6 months, 12 months
|
21-item self-report questionnaire.
Each item scored 0-3.
Total raw score range: minimum 0, maximum 63.
Higher score = more severe anxiety.
Clinical interpretation: 0-7 = minimal anxiety; 8-15 = mild anxiety; 16-25 = moderate anxiety; 26-63 = severe anxiety.
|
Baseline, 6 months, 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Body Shape Questionnaire-14 (BSQ-14) Score Change
Periodo de tiempo: Baseline, 6 months, 12 months
|
14-item self-report measure of body shape satisfaction.
Each item scored 1 (never) to 6 (always).
Total raw score range: minimum 14, maximum 84.
Lower score = greater body shape satisfaction (better).
Higher score = lower satisfaction (more dissatisfaction).
Clinical interpretation: score ≤ 34 = good satisfaction; score 35-50 = moderate dissatisfaction; score >50 = marked to severe dissatisfaction (poor satisfaction).
|
Baseline, 6 months, 12 months
|
|
General Health Questionnaire-28 (GHQ-28) - Likert Score
Periodo de tiempo: Baseline, 6 months, 12 months
|
28-item self-report screening tool for minor psychiatric disorders.
Likert scoring (0-1-2-3 per item) is used.
Total raw score range: minimum 0, maximum 84.
Higher score = worse psychological distress.
A total score greater than 23 suggests probable psychiatric caseness (anxiety or depression disorder).
Four subscales (each 0-21): A = somatic symptoms (items 1-7), B = anxiety/insomnia (8-14), C = social dysfunction (15-21), D = severe depression (22-28).
|
Baseline, 6 months, 12 months
|
|
Eating Attitude Test-26 (EAT-26) Score Change
Periodo de tiempo: Baseline, 6 months, 12 months
|
26-item screening tool for disordered eating attitudes.
Scoring: Always=3, Usually=2, Often=1, Sometimes=0, Rarely=0, Never=0.
Item 26 is reverse scored (Always=0, Never=3).
Total raw score range: minimum 0, maximum 78.
Higher score = more pathological eating attitudes.
A score of 20 or higher suggests possible eating disorder (anorexia nervosa, bulimia nervosa, or binge eating disorder) and needs clinical interview.
|
Baseline, 6 months, 12 months
|
|
Percent Total Weight Loss (%TWL)
Periodo de tiempo: 6 months, 12 months
|
Calculated as: [(Baseline weight in kg - current weight in kg) / baseline weight in kg] × 100.
Higher percentage = greater weight loss.
Can be negative if patient gains weight.
Successful weight loss after bariatric surgery is often defined as %TWL ≥ 20% at 12 months.
|
6 months, 12 months
|
|
Body Mass Index (BMI) Change
Periodo de tiempo: Baseline, 6 months, 12 months
|
Body Mass Index calculated as weight in kilograms divided by height in meters squared (kg/m²).
Weight measured using a calibrated scale; height measured at baseline using a stadiometer.
BMI range typically 15-60 kg/m² in this population.
Lower BMI indicates healthier weight status.
Clinical classification: <18.5 underweight, 18.5-24.9
normal, 25-29.9
overweight, 30-34.9
obesity class I, 35-39.9
obesity class II, ≥40 obesity class III (severe obesity).
|
Baseline, 6 months, 12 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Trastornos Nutricionales
- Sobrenutrición
- Peso corporal
- Hiperfagia
- Signos y Síntomas Digestivos
- Síntomas de comportamiento
- Exceso de peso
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Enfermedades Nutricionales y Metabólicas
- Signos y síntomas
- Bulimia
- Obesidad
- Desórdenes de ansiedad
- Depresión
- Terapéutica
- Procedimientos quirúrgicos, operativo
- Procedimientos quirúrgicos del sistema digestivo
- Anastomosis, quirúrgica
- Cirugía bariátrica
- Bariatría
- Gestión de la obesidad
- Gastroenterostomía
- Bypass gástrico
Otros números de identificación del estudio
- N-64-2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .